@hasantahir1990 Profile picture

Hasan Tahir

@hasantahir1990

Başıboş İt terörü karşıtı. #çözüm İtlaf

Joined September 2016
Similar User
Vecihi Hürkuş photo

@VecihiHrku17

Badem çiçeği photo

@eyma96580578

Neslihan Altınmakas photo

@NeslihanNmakas

kendihalindebiri photo

@karpuzcilekk1

Abdullah Allahın kulu photo

@AbdullahAllahn2

𝕬𝖍𝖒𝖊𝖉 𝖅𝖆𝖒𝖆𝖓𝖎 photo

@kendindehapis

BirGaribYolcu-Nur7 photo

@BirGarib_Yolcu_

dagistan photo

@dagistan7871

Arifhan Akpınar photo

@tutunanadam

BETÜL KÖROĞLU photo

@alkuu51405283

Nesibe photo

@Kardele77596770

mmmr ptkvk photo

@MPatkavak

@sivasim34581 photo

@zagorali33

Debreli Hasan photo

@debreli_hasan_

Serra-Said🌼 photo

@serra_said

Hasan Tahir Reposted

FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in #KRAS G12C #NSCLC @JTOonline 💊FGTI-2734 (farnesyltransferase + geranylgeranyltransferase-1) inhibits WT #RAS membrane localization &⬇️ sotorasib-induced ERK feedback reactivation. ✅This approach can…


Hasan Tahir Reposted

Hiçbir işi olmadığı için CHP Genel Başkanı olan Özgür Özel, İstanbul Cumhuriyet Başsavcısı Akın Gürlek için “başka iş bilmiyorsa avukatlık yapsın” demiş. Reçete okuyabiliyorsa Eczacı da olabilir bence! @eczozgurozel @herkesicinCHP

Özgür Özel'den İstanbul Cumhuriyet Başsavcısı Akın Gürlek'e: 📍 Başka iş bilmiyorsa avukatlık yapabilir 📍 Öyle aynayla konuşan başsavcıdan bize de kendisine de fayda yok t24.com.tr/haber/ozgur-oz…

Tweet Image 1


Hasan Tahir Reposted

Cancer cells impair monocyte-mediated T cell stimulation to evade immunity nature.com/articles/s4158…


Hasan Tahir Reposted

Excited to share our study on ALK-rearranged NSCLC! We report 3 cases of LCNEC transformation post-ALK-TKI, marking the first reported rate of histologic transformation (4%). Oncologists, be aware of this resistance mechanism! @IstTumori @ClinicalLung clinical-lung-cancer.com/article/S1525-…


Hasan Tahir Reposted

#ASH24 Autologous GPRC5D CAR-T, BMS-986393 Efficacy: - ORR: 96% (23/24); CRR: 46% (11/24). - MRD Negativity: 100% (5/5 with CR or better). - Ongoing Responses: 78% (18/23) at 5.9 months. Safety: - TRAEs: Any grade 97%, Grade 3/4 45%. - CRS: 84% (all Grade 1/2, resolved). -…

Tweet Image 1

Hasan Tahir Reposted

Kazachstania pintolopesii, a fungal symbiont transmitted by free-living mice, induces type 2 immunity to enhance resistance to helminth infections or aggravate gastrointestinal allergy nature.com/articles/s4158… @Nature @IlievLab

Tweet Image 1

Hasan Tahir Reposted

This is Lt. Colonel Alexander Vindman, a Purple Heart recipient and key witness for Trump’s first impeachment trial. As retribution for taking a stand, Elon Musk is hinting he could charged with treason based on false accusations. RETWEET if you stand with @AVindman!

Tweet Image 1

Hasan Tahir Reposted

Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation @Cancer_Cell sciencedirect.com/science/articl…


Hasan Tahir Reposted

Angela Merkel'in anı kitabından: "Erdoğan'ın karşısında sarayına gittiğimde orada sindiğim ve gerekirse kendimi onun önünde yerlere bile çökebileceğim yazıldı. Ancak biz o sırada Türkiye ile daha fazla mülteciyi bizden uzak tutabilecek bir anlaşma imzalamak üzereydik."

Tweet Image 1

Hasan Tahir Reposted

I’m excited to share new work out of the lab in @NatMetabolism today on the impact of tumor-relevant glucose concentrations on the response to pyrimidine synthesis inhibitors. nature.com/articles/s4225…. PDF: rdcu.be/d1vkV


Hasan Tahir Reposted

Nuvectis reports no dose-limiting toxicities to date in trial of NXP900. Per @Nuvectis, drug targets SRC/YES1 kinase & “holds potential for combination therapies with #EGFR and #ALK inhibitors” for pts with TKI-resistant lung cancer #NSCLC #ALKPositive usawire.com/on-the-cusp-of…


Hasan Tahir Reposted

In 2021, Tina was diagnosed with Stage 4 ALK+ lung cancer. It was a shock—especially as a never-smoker—but she refuses to let it stop her from making plans and enjoying life. A proud mum of two and devoted grandma to her beautiful grandson Archie, Tina is focused on spending…

Tweet Image 1

Hasan Tahir Reposted

Sakin ol şampiyon. Önce MİT Başkanı İbrahim Kalın’a sor. Belki TERÖRİST falandır! @ikalin1 @eczozgurozel


Hasan Tahir Reposted

Old dog, new tricks. Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. @MangusoLab @kathleenbyates Fiona A. Harding etc. cell.com/immunity/fullt…


Hasan Tahir Reposted

New #JITC article: TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion bit.ly/3ZbNFO6 @ElianePiaggio

Tweet Image 1

Hasan Tahir Reposted

Combining two treatments that activate myeloid cells may prove successful against tumors where conventional T cell-based immunotherapies have failed, indicates @SciImmunology research in mouse models of pancreatic cancer. Learn more on #WorldPancreaticCancerDay:…

Tweet Image 1

Hasan Tahir Reposted

💡New Insights Dr. Claudio Brancolini's team from @uniud highlight the crucial role of zinc-dependent HDACs in #Cancer drug resistance, could be key targets to reverse resistance, especially with new family-specific inhibitors on the market! 🧬oaepublish.com/articles/cdr.2…

Tweet Image 1
Tweet Image 2

Hasan Tahir Reposted

Phase I study of next-gen #ALK #ROS1 TKI deulorlatinib @JTOonline AEs include lipids & weight gain; 1.5% d/c for AE. Deulorlatinib 60mg in ALK: 1L RR 88%, icRR 75%, DOR NR. Post 2G TKI, RR 38%, icRR 70%, DOR NR. Post crizotinib RR 71%, DOR 18m. jto.org/article/S1556-…


Hasan Tahir Reposted

Avukat Dilek Ekmekçi süresiz açlık grevine başlama kararı almış. Tüm barolar, duyarlı tüm insanlar destek verip bu hukuksuzluğu durdurmalıyız. @barolar @istbarosu

Dilek açlık grevine başlıyor. El yazısıyla gönderdiği açıklamasını paylaşıyorum #DilekEkmekçiyeÖzgürlük #dilekekmekciserbestbırakılsın

Tweet Image 1


Loading...

Something went wrong.


Something went wrong.